Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419623 · ClinicalTrials.gov registry record · Phase 1
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
A Phase 1 study, sponsored by Telios Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04419623: Completed Phase 1 study, sponsored by Telios Pharma.
NCT04419623 is a Phase 1 study that has completed, run by Telios Pharma. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04419623, a Phase 1 study, has completed, sponsored by Telios Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.
Primary Outcome
To determine the recommended dose of TL-895 to be based on the observed dose limiting toxicity
Interventions
- DRUG TL-895
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 1 |
What the finished NCT04419623 record still lists
NCT04419623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which TL-895 is the first listed.
NCT04419623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04419623 about?
NCT04419623 is a clinical study titled "A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer". This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was e...
What is the current status of trial NCT04419623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-07-09. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT04419623?
The interventions under investigation include: TL-895 (DRUG).
Who is sponsoring clinical trial NCT04419623?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04419623's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI